chr19-53992881-A-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_145814.2(CACNG6):c.4A>T(p.Met2Leu) variant causes a missense change. The variant allele was found at a frequency of 0.00000143 in 1,396,000 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 33)
Exomes 𝑓: 8.0e-7 ( 0 hom. )
Consequence
CACNG6
NM_145814.2 missense
NM_145814.2 missense
Scores
2
7
10
Clinical Significance
Conservation
PhyloP100: 4.86
Genes affected
CACNG6 (HGNC:13625): (calcium voltage-gated channel auxiliary subunit gamma 6) Voltage-dependent calcium channels are composed of five subunits. The protein encoded by this gene represents one of these subunits, gamma, and is one of two known gamma subunit proteins. This particular gamma subunit is an integral membrane protein that is thought to stabilize the calcium channel in an inactive (closed) state. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members that function as transmembrane AMPA receptor regulatory proteins (TARPs). Alternative splicing results in multiple transcript variants. Variants in this gene have been associated with aspirin-intolerant asthma. [provided by RefSeq, Dec 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNG6 | NM_145814.2 | c.4A>T | p.Met2Leu | missense_variant | 1/4 | ENST00000252729.7 | NP_665813.1 | |
CACNG6 | NM_145815.2 | c.4A>T | p.Met2Leu | missense_variant | 1/3 | NP_665814.1 | ||
CACNG6 | NM_031897.3 | c.4A>T | p.Met2Leu | missense_variant | 1/2 | NP_114103.2 | ||
CACNG6 | NR_102308.2 | n.49+1684A>T | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNG6 | ENST00000252729.7 | c.4A>T | p.Met2Leu | missense_variant | 1/4 | 1 | NM_145814.2 | ENSP00000252729 | P1 | |
CACNG6 | ENST00000346968.2 | c.4A>T | p.Met2Leu | missense_variant | 1/3 | 5 | ENSP00000319097 | |||
CACNG6 | ENST00000352529.1 | c.4A>T | p.Met2Leu | missense_variant | 1/2 | 5 | ENSP00000319135 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 151990Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
1
AN:
151990
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 8.04e-7 AC: 1AN: 1244010Hom.: 0 Cov.: 30 AF XY: 0.00000165 AC XY: 1AN XY: 606138
GnomAD4 exome
AF:
AC:
1
AN:
1244010
Hom.:
Cov.:
30
AF XY:
AC XY:
1
AN XY:
606138
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000658 AC: 1AN: 151990Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74214
GnomAD4 genome
AF:
AC:
1
AN:
151990
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74214
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 09, 2022 | The c.4A>T (p.M2L) alteration is located in exon 1 (coding exon 1) of the CACNG6 gene. This alteration results from a A to T substitution at nucleotide position 4, causing the methionine (M) at amino acid position 2 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Benign
DEOGEN2
Benign
.;T;.
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T;T
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;M;.
MutationTaster
Benign
D;D;D
PrimateAI
Pathogenic
D
PROVEAN
Benign
N;N;N
REVEL
Benign
Sift
Pathogenic
D;D;D
Sift4G
Benign
T;T;T
Polyphen
P;P;P
Vest4
MutPred
Loss of MoRF binding (P = 0.1087);Loss of MoRF binding (P = 0.1087);Loss of MoRF binding (P = 0.1087);
MVP
MPC
1.3
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at